MannKind Corporation reported second quarter 2026 revenues of $109.4 million, a 43% increase year-over-year, driven by the inclusion of Furoscix sales and higher collaboration revenue. The company posted a net loss of $0.06 per share, missing analyst expectations due to a significant rise in operating expenses to support recent product approvals and launches.
Key Highlights
- Total revenue grew 43% year-over-year to $109.4 million, slightly ahead of the $108.8 million consensus estimate.
- Reported a net loss of $0.06 per share, missing expectations for a $0.02 loss, as SG&A expenses rose 84% to $58.3 million to support new launches.
- Newly acquired Furoscix generated $22.2 million in net sales, while Afrezza sales were $17.0 million.
- The company secured two key FDA approvals: the pediatric indication for Afrezza and the Furoscix ReadyFlow autoinjector, which is expected to be commercially available in late August.